Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced ovarian carcinoma of epithelial origin.

Israel - English - Ministry of Health

abic marketing ltd, israel - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - carboplatin - carboplatin - advanced ovarian carcinoma in initial treatment and secondary treatment.metastatic small cell carcinoma of the lung.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced ovarian carcinoma of epithelial origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced ovarian carcinoma of epithelial origin.

Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously trea

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin is indicated in the treatment of: advanced stage ovarian cancer of epithelial origin; small cell lung carcinoma; carcinoma of the head and neck; carcinoma of the testis; paediatric cerebral tumours; soft tissue sarcoma; neuroblastoma.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hikma farmacêutica s.a. - carboplatin 50 mg/5 ml - solution for infusion - 10 mg/ml - carboplatin 10 mg/ml - carboplatin